Trial Profile
DEFEND 2: Durable-Response Therapy Evaluation For Early- or New-Onset Type 1 Diabetes.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Otelixizumab (Primary)
- Indications Type 1 diabetes mellitus
- Focus Biomarker; Registrational; Therapeutic Use
- Acronyms DEFEND 2A; DEFEND-2
- Sponsors GlaxoSmithKline; GSK
- 06 Apr 2022 This trial has been completed in Netherland (Global end date: 09/03/2012), according to European Clinical Trials Database record.
- 06 Apr 2022 This trial has been completed in Netherland (Global end date: 09/03/2012), according to European Clinical Trials Database record.
- 01 Nov 2016 Results of urinary C-peptide analysis published in the Diabetic Medicine